share_log

Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today

为什么 TransCode Therapeutics（RNAZ）的股票今天交易走高
Benzinga Real-time News ·  2023/02/01 07:52
  • TransCode Therapeutics Inc (NASDAQ:RNAZ) reported preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.
  • TTX-RIGA, a novel immunotherapeutic cancer candidate, is designed to work by binding to an intracellular receptor called RIG-I (retinoic acid-inducible gene I), expected to result in targeted activation of innate immunity in the tumor microenvironment.
  • In preclinical studies, TransCode's delivery of TTX-RIGA inside tumors and metastases generated an RNA-based agonist of the RIG-I gene, targeting the activation of innate immunity in the tumor microenvironment in multiple solid tumors.
  • "As with prior studies, we believe the data from this preclinical study further support the advancement of TTX-RIGA into animal studies slated to begin in February 2023," commented Zdravka Medarova, co-founder & CTO of TransCode.
  • "We believe that demonstrating successful preclinical results with TTX-RIGA is an important step in the preclinical development process and further de-risks our pipeline that includes multiple RNA approaches," added Michael Dudley, co-founder, president, and CEO of TransCode.
  • Dudley added, "we received written authorization from the FDA to proceed with our Phase 0 first-in-human (FIH) clinical trial with our lead candidate, TTX-MC138, in cancer patients with advanced solid tumors. We intend to proceed with patient enrollment as soon as possible."
  • Price Action: RNAZ shares are up 43.90% at $1.08 during the premarket session on the last check Wednesday.
  • TransCode Therap 纳斯达克股票代码：RNAZ）报告了其候选免疫疗法TTX-RIGA在黑色素瘤中的临床前机制验证研究。
  • TTX-RIGA是一种新型的免疫治疗癌症候选药物，旨在通过与一种名为RIG-I（维甲酸诱导基因 I）的细胞内受体结合起作用，该受体有望在肿瘤微环境中靶向激活先天免疫。
  • 在临床前研究中，TransCode在肿瘤和转移瘤内输送TTX-RIGA生成了一种基于RNA的RIG-I基因激动剂，靶向激活多个实体瘤肿瘤微环境中的先天免疫。
  • TransCode联合创始人兼首席技术官兹德拉夫卡·梅达罗娃评论说：“与先前的研究一样，我们相信这项临床前研究的数据进一步支持了定于2023年2月开始的TTX-RIGA进入动物研究。”
  • TransCode联合创始人、总裁兼首席执行官迈克尔·达德利补充说：“我们认为，使用TTX-RIGA展示成功的临床前结果是临床前开发过程中的重要一步，可以进一步降低包括多种RNA方法在内的产品线的风险。”
  • 达德利补充说：“我们获得了美国食品药品管理局的书面授权，可以继续对晚期实体瘤癌症患者进行我们的第一人体（FIH）的0期首次人体（FIH）临床试验。TTX-MC138我们打算尽快进行患者入组。”
  • 价格走势： 在周三最后一次支票的盘前交易中，RNAZ股价上涨了43.90％，至1.08美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发